It was not tested on prostate cancer but they are planning to do it, plus it's anyway a promising result!
A phase 1 trial of the personalized cancer vaccine PGV001 has shown promising immune responses in patients with various tumor types, including lung, breast, head and neck, urothelial cancers, and multiple myeloma.
The vaccine targets neoantigens, which are unique mutations specific to each patient’s tumor, allowing for a highly tailored immune response.
Thirteen patients who had completed standard therapies received the vaccine, which was well tolerated with no serious side effects.
At a five-year follow-up, six patients were still alive, and three remained tumor-free.
These results suggest that PGV001 may help prevent recurrence by priming the immune system for long-term cancer control.
